clinical trial · NCT03920228
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
Pachyonychia CongenitaPTX-022Placebo
brief summary
This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita. This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.
started
Apr 1, 2019
primary completion
Sep 19, 2020
completion
Oct 19, 2020
last updated
Aug 29, 2024
official title
A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol